167 related articles for article (PubMed ID: 27036032)
1. Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma.
Wang WL; Chang WL; Yang HB; Wang YC; Chang IW; Lee CT; Chang CY; Lin JT; Sheu BS
Oncotarget; 2016 Nov; 7(44):71169-71181. PubMed ID: 27036032
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.
Hannigan A; Smith P; Kalna G; Lo Nigro C; Orange C; O'Brien DI; Shah R; Syed N; Spender LC; Herrera B; Thurlow JK; Lattanzio L; Monteverde M; Maurer ME; Buffa FM; Mann J; Chu DC; West CM; Patridge M; Oien KA; Cooper JA; Frame MC; Harris AL; Hiller L; Nicholson LJ; Gasco M; Crook T; Inman GJ
J Clin Invest; 2010 Aug; 120(8):2842-57. PubMed ID: 20592473
[TBL] [Abstract][Full Text] [Related]
3. Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis.
Anupam K; Tusharkant C; Gupta SD; Ranju R
World J Gastroenterol; 2006 Oct; 12(37):6041-5. PubMed ID: 17009406
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of HIC1 promotes epithelial-mesenchymal transition and drives progression in esophageal squamous cell carcinoma.
Li P; Liu X; Dong ZM; Ling ZQ
Oncotarget; 2015 Nov; 6(35):38151-65. PubMed ID: 26510908
[TBL] [Abstract][Full Text] [Related]
5. CpG island hypermethylation of E-cadherin (CDH1) and integrin alpha4 is associated with recurrence of early stage esophageal squamous cell carcinoma.
Lee EJ; Lee BB; Han J; Cho EY; Shim YM; Park J; Kim DH
Int J Cancer; 2008 Nov; 123(9):2073-9. PubMed ID: 18697202
[TBL] [Abstract][Full Text] [Related]
6. Loss of Disabled-2 Expression in Pancreatic Cancer Progression.
Hocevar BA
Sci Rep; 2019 May; 9(1):7532. PubMed ID: 31101868
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-β1-induced epithelial-mesenchymal transition in human esophageal squamous cell carcinoma via the PTEN/PI3K signaling pathway.
Zhang HY; Wang ZQ; Li YY; Wang F; Zeng QR; Gao Y; Xuan XY; Li SS
Oncol Rep; 2014 Nov; 32(5):2134-42. PubMed ID: 25175594
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of LGI1 promotes tumor metastasis in esophageal squamous cell carcinoma.
Zhu YH; Liu H; Zhang LY; Zeng T; Song Y; Qin YR; Li L; Liu L; Li J; Zhang B; Guan XY
Carcinogenesis; 2014 May; 35(5):1154-61. PubMed ID: 24510112
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
Chao A; Lin CY; Lee YS; Tsai CL; Wei PC; Hsueh S; Wu TI; Tsai CN; Wang CJ; Chao AS; Wang TH; Lai CH
Oncogene; 2012 Feb; 31(6):764-75. PubMed ID: 21725366
[TBL] [Abstract][Full Text] [Related]
10. Disabled-2 downregulation promotes epithelial-to-mesenchymal transition.
Martin JC; Herbert BS; Hocevar BA
Br J Cancer; 2010 Nov; 103(11):1716-23. PubMed ID: 21063401
[TBL] [Abstract][Full Text] [Related]
11. High endothelin-converting enzyme-1 expression independently predicts poor survival of patients with esophageal squamous cell carcinoma.
Wu CF; Lee CT; Kuo YH; Chen TH; Chang CY; Chang IW; Wang WL
Tumour Biol; 2017 Sep; 39(9):1010428317725922. PubMed ID: 28945168
[TBL] [Abstract][Full Text] [Related]
12. [Expressions of Dab2 and ERK1 in esophageal carcinoma tissues and their clinical significance].
Pang X; Ma Y; Qu Y; Yang H; Gao D
Zhonghua Yi Xue Za Zhi; 2014 May; 94(18):1416-8. PubMed ID: 25142995
[TBL] [Abstract][Full Text] [Related]
13. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers.
Xie XM; Zhang ZY; Yang LH; Yang DL; Tang N; Zhao HY; Xu HT; Li QC; Wang EH
Int J Oncol; 2013 Nov; 43(5):1636-42. PubMed ID: 24002585
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-106b is involved in transforming growth factor β1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma.
Cheng Y; Guo Y; Zhang Y; You K; Li Z; Geng L
J Exp Clin Cancer Res; 2016 Jan; 35():11. PubMed ID: 26769181
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of the novel tumor suppressor DIRAS1 predicts poor prognosis in esophageal squamous cell carcinoma.
Zhu YH; Fu L; Chen L; Qin YR; Liu H; Xie F; Zeng T; Dong SS; Li J; Li Y; Dai Y; Xie D; Guan XY
Cancer Res; 2013 Apr; 73(7):2298-309. PubMed ID: 23436800
[TBL] [Abstract][Full Text] [Related]
16. SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer.
Nishimura T; Tamaoki M; Komatsuzaki R; Oue N; Taniguchi H; Komatsu M; Aoyagi K; Minashi K; Chiwaki F; Shinohara H; Tachimori Y; Yasui W; Muto M; Yoshida T; Sakai Y; Sasaki H
Cancer Sci; 2017 Feb; 108(2):216-225. PubMed ID: 27987372
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
[TBL] [Abstract][Full Text] [Related]
18. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin-B-mediated cleavage of Disabled-2 regulates TGF-β-induced autophagy.
Jiang Y; Woosley AN; Sivalingam N; Natarajan S; Howe PH
Nat Cell Biol; 2016 Aug; 18(8):851-63. PubMed ID: 27398911
[TBL] [Abstract][Full Text] [Related]
20. MiR-93 functions as a tumor promoter in prostate cancer by targeting disabled homolog 2 (DAB2) and an antitumor polysaccharide from green tea (Camellia sinensis) on their expression.
Yang K; Li YW; Gao ZY; Xiao W; Li TQ; Song W; Zheng J; Chen H; Chen GH; Zou HY
Int J Biol Macromol; 2019 Mar; 125():557-565. PubMed ID: 30543885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
